Co-Diagnostics Inc (CODX) concluded trading on Thursday at a closing price of $0.25, with 12.2 million shares of worth about $3.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -74.81% during that period and on July 10, 2025 the price saw a loss of about -10.58%. Currently the company’s common shares owned by public are about 33.57M shares, out of which, 30.68M shares are available for trading.
Stock saw a price change of -11.92% in past 5 days and over the past one month there was a price change of -15.50%. Year-to-date (YTD), CODX shares are showing a performance of -79.69% which decreased to -66.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.23 but also hit the highest price of $2.23 during that period. The average intraday trading volume for Co-Diagnostics Inc shares is 597.44K. The stock is currently trading -7.85% below its 20-day simple moving average (SMA20), while that difference is down -14.36% for SMA50 and it goes to -62.78% lower than SMA200.
Co-Diagnostics Inc (NASDAQ: CODX) currently have 33.57M outstanding shares and institutions hold larger chunk of about 17.44% of that.
The stock has a current market capitalization of $8.49M and its 3Y-monthly beta is at 0.53. It has posted earnings per share of -$1.14 in the same period. It has Quick Ratio of 4.23 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CODX, volatility over the week remained 8.41% while standing at 8.64% over the month.
Analysts are in expectations that Co-Diagnostics Inc (CODX) stock would likely to be making an EPS of -0.25 in the current quarter, while forecast for next quarter EPS is -0.16 and it is -0.34 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.25 which is -0.25 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.24 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 13.71% while it is estimated to increase by 60.75% in next year. EPS is likely to grow at an annualized rate of 37.69% for next 5-years, compared to annual growth of -27.40% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Sidoti on August 12, 2022 offering a Neutral rating for the stock and assigned a target price of $5 to it. Coverage by Sidoti stated Co-Diagnostics Inc (CODX) stock as a Buy in their note to investors on December 29, 2021, suggesting a price target of $14 for the stock. Stock get a Buy rating from H.C. Wainwright on May 18, 2020.